Introduction
============

Stomatal closure is an adaptation to conserve water loss during drought/water stress conditions. During the stress conditions, the synthesis and mobilization of abscisic acid (ABA) form key physiological events, facilitating stomatal closure by ABA ([@bib24]; [@bib3]). In view of the powerful effects of ABA, the signalling components during ABA-induced stomatal closure have been examined extensively ([@bib9]; [@bib29]; [@bib1]; [@bib11]). Protein phosphatases such as ABI1, ABI2, and HAB1 are negative regulators during ABA-induced stomatal closure, while protein kinases such as SnRK2s (including OST1) are positive regulators ([@bib18]; [@bib13]; [@bib10]; [@bib11]). Other protein kinases such as CBLs and CIPKs also play crucial roles in ABA-induced stomatal closure. In addition, ABA promotes the activity of anion channels (e.g. SLAK1, AtALMT12) and down-regulates the activity of inward K^+^ channels (KAT1and KAT2) in stomatal guard cells ([@bib5]; [@bib12]; [@bib27]; [@bib11]). Besides the above signalling components, participation of several small molecules like reactive oxygen species (ROS), nitric oxide (NO), and ions like Ca^2+^, besides a rise in guard cell pH are all essential during ABA-mediated stomatal closure ([@bib19]; [@bib28]; [@bib6], [@bib7]).

Despite repeated attempts, the identity of ABA putative receptors was not established for a long time. In 2009, two independent groups identified and established that PYR/PYL/RCAR proteins, that belong to the cyclase subfamily of the START/Bet v I protein superfamily, acted as ABA receptors in *Arabidopsis* ([@bib14]; [@bib22]). Soon after, the crystallization, molecular modelling, and simulation of the structure of PYR/PYL/RCAR proteins unravelled the novel mechanisms of their function ([@bib20]; [@bib30]; [@bib15]). In the absence of ABA, PP2Cs keep the pool of SnRK2s dephosphorylated and limit the phosphorylation of transcription factors involved in ABA-induced gene expression. When present, ABA binds to PYR/PYL and then to PP2C making a functional complex, and blocks the normal function of PP2C. As a result, the SnRK2s stay in a phosphorylated state and activate the transcription factors and induce ABA-activated gene expression ([@bib4]; [@bib16]; [@bib23]).

The identification of PYR/PYL proteins as ABA receptors was made possible by the discovery of pyrabactin (4-bromo-N-(pyridine-2-yl methyl) naphthalene-1-sulfonamide), a synthetic compound. Pyrabactin was found to suppress markedly seed germination and hypocotyl growth, besides the promotion of gene expression, very similar to the pattern with ABA ([@bib22]). Pyrabactin was considered as a potential anti-transpirant/stress adaptor, with possible uses in agriculture. It became clear that pyrabactin was acting as an agonist during ABA action. The expression of *pyr/pyl* mRNA was quite high not only in the seeds, but also in guard cells. In addition, the *Arabidopsis* quadruple mutants lacking *pyr1pyl1pyl2pyl4* were impaired in ABA-induced stomatal closure and the ABA-inhibition of stomatal opening ([@bib21]). All these studies imply that pyrabactin must affect guard cell function and stomatal closure. However, there have been no direct detailed experiments on stomatal closure in response to pyrabactin. In this report, the response of *Pisum sativum* guard cells to pyrabactin during stomatal closure was studied and the effects with ABA were compared. The effect of ABA on stomatal closure was examined in detail as well as changes in the signalling components, including pH, ROS, and NO. The influence of pyrabactin on stomata was then examined in the absence/presence of ABA and vice versa. Attempts were made to determine the apparent *K*~D~ for pyrabactin and ABA.

Materials and methods
=====================

Chemicals
---------

Pyrabactin and apyrabactin were from Sigma-Aldrich and Chembridge Corporation (San Diego, CA), respectively. DAF-2DA was from Calbiochem (Rockland, MA). BCECF-AM was from Invitrogen (Molecular Probes). The remaining chemicals were from Sigma-Aldrich. The stock solutions of ABA and fusicoccin were prepared in ethanol and methanol, respectively. The stocks of pyrabactin, apyrabactin, fluorescent probes, and DPI were in DMSO and all the remaining chemicals were in milli Q water. Stock solutions were prepared in such a way that the final concentration of solvent was \<0.2% in the final medium.

Plant materials and growth conditions
-------------------------------------

Plants of pea (*Pisum sativum* L., cv. Arkel) were raised from seeds, procured from Pocha Seeds, Pune, India. The plants were grown outdoors under a natural photoperiod of approximately 12 h and an average temperature of 30/20 °C day/night. The second pair of fully unfolded leaves was picked at about 09.00 h from 9--15-d-old plants for subsequent use.

Stomatal closure in epidermal strips
------------------------------------

The abaxial epidermis was peeled from the leaves and cut into pieces of *c.* 0.4 cm^2^. Twenty-five epidermal strips were transferred to 3 cm diameter Petri dishes containing 3 ml of opening medium (10 mM MES-KOH, pH 7.0, and 50 mM KCl). The epidermal strips were exposed to a bank of tungsten lamps, whose light was filtered through water jacket white light of 200---250 μmol m^−2^ s^−1^, for 150 min, to get maximum stomatal opening. Photon flux was measured with a Li-Cor quantum sensor (Li-Cor Instruments Ltd, Lincoln, NE, USA). The temperature was maintained at 25±1 °C. After 150 min of illumination, three epidermal strips were transferred to each of 24 well plates, containing medium and the required concentrations of ABA, pyrabactin or test compounds (inhibitors or scavengers). Illumination was continued for the next 120 min, before measuring stomatal apertures. When used together, the test compounds were added 15 min prior to the addition of ABA or pyrabactin.

The width of the stomatal apertures was measured under a research microscope with the help of a precalibrated ocular micrometer. 10---15 apertures were monitored at random in each of three different epidermal strips, from each treatment. The experiments were repeated on at least three different days, making each measurement of stomatal aperture an average of a minimum of 90 stomata.

Fluorescent probes to monitor ROS, NO or cytoplasmic pH changes
---------------------------------------------------------------

Changes in ROS, NO or cytoplasmic pH levels in guard cells were monitored by using respective fluorescent probes, 2′,7′-dichlorofluorescien diacetate (H~2~DCF-DA); 4, 5-diaminofluorescein diacetate (DAF-2DA); or 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein), acetoxymethyl ester (BCECF-AM) ([@bib17]; [@bib19]; [@bib6]). Epidermal peels were mounted on a microscope slide with medical adhesive Telesis V (Premiere Products Inc., Pacaima, California, USA). Stomata were allowed to open by incubating epidermal tissues under 200--250 μmol m^−2^ s^−1^ white light for 150 min, in a medium of 10 mM MES-KOH, pH 7.0, and 50 mM KCl. After 150 min, the epidermal tissues were loaded with 30 μM H~2~DCF-DA, 10 μM DAF-2DA or 5 μM BCECF-AM (30 min in dark), respectively, at 25±1 °C. The strips were rinsed with incubation buffer, to wash off excessive fluorophore. For studying time-course changes in ROS/NO/pH levels, the epidermal tissues were treated with 20 μM ABA or 20 μM pyrabactin, at zero-time and changes in fluorescence levels were measured at 3 min intervals. In the control sets, an equal and appropriate volume of ethanol or DMSO was added. Modulators were added 10 min prior to the addition of 20 μM ABA or 20 μM pyrabactin. The data are representative of the averages ±SE of three independent experiments, with measurements on a minimum of 60 individual stomata.

For time-course measurements, guard cells were observed under an inverted fluorescence microscope (Optiphot-2, Nikon, Japan) fitted with a monochrome high-resolution digital cooled CD camera (Cool snap FX) that enabled the quick capture of images, for further analysis later on. The captured images and the relative fluorescence emission of guard cells were analysed by using NIH Image for Windows ([@bib17]; [@bib28]). Fluorescence intensity was measured in pixels in a scale of 0 (darkest) to 250 (brightest). The fluorescence intensity in the guard cells, without ABA, pyrabactin or any effectors (at the beginning of the experiment), was taken as 100% ([@bib28]; [@bib6]). In some of the experiments (as indicated in the figure legends), a confocal microscope (TCSSP-2, AOBS 4 channel UV and visible; Leica, Heidelberg, Germany) was used to observe the changes in fluorescence indicating ROS, NO or cytoplasmic pH.

Results
=======

Pyrabactin induced stomatal closure and changes in ROS, NO, and cytoplasmic pH levels in guard cells
----------------------------------------------------------------------------------------------------

ABA or its analogue pyrabactin caused stomatal closure in a concentration-dependent manner. The concentrations of ABA or pyrabactin, required for maximal stomatal closure, were quite similar ([Fig. 1a, b](#fig1){ref-type="fig"}). By contrast, apyrabactin, an inactive analogue of ABA, did not have any significant effect on stomata ([Fig. 1c](#fig1){ref-type="fig"}). The presence of fusicoccin (FC, a fungal toxin) prevented the stomatal closure caused by either ABA or pyrabactin ([Fig. 2](#fig2){ref-type="fig"}).

![Effect of ABA, pyrabactin or apyrabactin concentrations on stomata in abaxial epidermis of *Pisum sativum*. ABA or pyrabactin caused marked stomatal closure in a similar pattern, while apyrabactin did not have any significant effect. The data are averages of three independent experiments ±SE.](jexboterr364f01_lw){#fig1}

![Effect of fungal toxin, fusicoccin (FC), on stomatal closure caused by ABA or pyrabactin. Fusicoccin completely relieved stomatal closure by ABA or pyrabactin. The data are means of three experiments ±SE.](jexboterr364f02_ht){#fig2}

Pyrabactin increased ROS, NO, and cytoplasmic pH levels in guard cells within a few minutes after treatment, when compared with their respective controls ([Fig. 3](#fig3){ref-type="fig"}). Apyrabactin, an inactive analogue of ABA, did not cause any noticeable changes in ROS/NO/pH of guard cells ([Fig. 3d, h, l](#fig3){ref-type="fig"}). The initial rise of H~2~DCF-DA fluorescence (indicating ROS levels) was seen at 6 min after treatment and fluorescence peaked between 18--24 min ([Fig. 4a](#fig4){ref-type="fig"}). Similarly, NO-specific DAF-2DA fluorescence (indicating NO) showed an initial rise at 9 min after treatment and fluorescence peaked after 18 min of treatment ([Fig. 4b](#fig4){ref-type="fig"}). The BCECF-AM fluorescence (reflecting the pH) initially increased within 3 min and peaked after 24 min ([Fig. 4c](#fig4){ref-type="fig"}). A similar pattern of changes were observed with ABA.

![Representative confocal images showing the changes in ROS, NO, and cytoplasmic pH changes in *Pisum sativum* guard cells in the presence or absence of ABA, pyrabactin or apyrabactin. (a--d) Changes in ROS levels as indicated by H~2~DCF-DA fluorescence. (e--h) Changes in NO levels as indicated by DAF2-DA fluorescence. (i--l) Changes in cytoplasmic pH levels as indicated by BCECF-AM fluorescence. ABA or pyrabactin increased the levels of ROS, NO, and cytoplasmic pH, compared to respective controls. (This figure is available in colour at *JXB* online.)](jexboterr364f03_3c){#fig3}

![Changes with time in fluorescence of guard cells, loaded with fluorescent probes specific for ROS, NO or pH. The fluorescence was monitored at different times after exposure to pyrabactin or ABA, using an inverted fluorescence microscope. The details are described in the Materials and methods. ABA or pyrabactin increased with time in the fluorescence intensities of H~2~DCF-DA, DAF2-DA, and BCECF-AM reflecting the rise in ROS, NO, and pH of guard cells. The effects of pyrabactin and ABA were quite similar. The data are averages ±SE of three independent experiments, each representing a minimum of 60 individual stomata.](jexboterr364f04_lw){#fig4}

Modulators of ROS/NO/pH can relieve pyrabactin-induced stomatal closure and dampen the rise in ROS, NO or pH levels of guard cells
----------------------------------------------------------------------------------------------------------------------------------

ROS modulators: DPI (NADPH oxidase inhibitor) or catalase (H~2~O~2~ scavenging enzyme), partially relieved stomatal closure by ABA or pyrabactin. Similarly, stomatal closure by ABA or pyrabactin was compromised in the presence of either cPTIO (NO scavenger), or L-NAME (nitric oxide synthase inhibitor) or tungstate (nitrate reductase inhibitor). Butyrate (a weak acid), relieved stomatal closure induced by ABA or pyrabactin ([Fig. 5](#fig5){ref-type="fig"}).

![The effect of ROS, NO or pH modulators on stomatal closure caused by ABA or pyrabactin. The decrease in stomatal aperture by ABA or pyrabactin was relieved by ROS modulators, catalase or DPI (a), NO modulators cPTIO and L-NAME or tungstate (b), and pH modulator, butyrate (c). The data are means ±SE of three independent experiments, each representing a minimum of 90 individual stomata.](jexboterr364f05_ht){#fig5}

Catalase completely relieved the increase in H~2~DCF-DA fluorescence by pyrabactin or ABA, while DPI had a partial effect, conforming the increase in fluorescence due to ROS ([Fig. 6](#fig6){ref-type="fig"}). DAF-2DA fluorescence increase by ABA or pyrabactin was abolished by cPTIO (NO scavenger). Similarly, L-NAME or tungstate (inhibitors of NO synthase or nitrate reductase) restricted the DAF-2DA fluorescence increase by ABA or pyrabactin. Butyrate restricted the rise in BCECF-AM fluorescence by ABA or pyrabactin.

![Effect of ROS, NO or pH modulators on H~2~DCF-DA, DAF2-DA, or BCECF-AM fluorescence levels respectively. Changes in fluorescence levels were monitored by using an inverted fluorescence microscope. (a) ROS modulators, catalase or DPI, prevented ABA or pyrabactin-induced increase of H~2~DCF-DA fluorescence. (b) NO modulators, cPTIO and L-NAME or tungstate, prevented ABA- or pyrabactin-induced increase of DAF2-DA fluorescence. (c) Butyrate, a pH modulator, restricted the ABA- or pyrabactin-induced increase in BCECF-AM fluorescence. The data are averages ±SE of three independent experiments, each with a minimum of 60 individual stomata.](jexboterr364f06_ht){#fig6}

Pyrabactin competes with ABA during stomatal closure
----------------------------------------------------

Experiments using varied concentrations of pyrabactin (0--100 μM), in the absence or presence of 5 μM ABA and vice-versa (varied concentrations of ABA in the absence or presence of 5 μM pyrabactin), revealed that the effects of ABA and pyrabactin were additive ([Fig. 7](#fig7){ref-type="fig"}). Kinetic analyses of these data indicated that the apparent *IC*~50~ of pyrabactin or ABA did not change much in the presence of ABA or pyrabactin ([Fig. 7a, b](#fig7){ref-type="fig"}). By contrast, the double reciprocal plots using low concentrations of varied concentrations of ABA or pyrabactin (0.5--5 μM) in the absence or presence of 5 μM pyrabactin or ABA demonstrated that the *K*~D~ of ABA increased by almost 4-fold in the presence of pyrabactin and the *K*~D~ of pyrabactin increased by nearly 3-fold in the presence of ABA ([Fig. 7c, d](#fig7){ref-type="fig"}).

![Additive effect of ABA and pyrabactin during stomatal closure. (a) The apparent *IC*~50~ of ABA changed from 4.26 μM to 4.88 μM in the presence of 5 μM pyrabactin, when the change in stomatal closure was plotted as a function of concentration of ABA. (b) The apparent *IC*~50~ of pyrabactin changed from 4.47 μM to 5.05 μM in the presence of 5 μM ABA, when the change in stomatal closure was plotted as a function of concentration of pyrabactin. (c) The double reciprocal plot showing the increase of the apparent *K*~D~ of ABA, almost 4-fold, from 1.08 μM to 3.82 μM in the presence of 5 μM pyrabactin. (d) The double reciprocal plot demonstrated that the apparent *K*~D~ of pyrabactin increased by almost 3-fold from 1.17 μM to 3.05 μM in the presence of 5 μM ABA. The marked increase in *K*~D~ of ABA/pyrabactin in the presence of pyrabactin/ABA suggested their competition at or near their binding site during stomatal closure. The data are the average means of three independent experiments.](jexboterr364f07_lw){#fig7}

Discussion
==========

Pyrabactin, a synthetic ABA analogue, is considered to be a potential tool in future agriculture. Initially identified as a seed germination inhibitor, pyrabactin led the way for the identification, purification, and characterization of ABA receptors. Most of the earlier experiments with pyrabactin were done on either germinating seeds or *in vitro* reconstituted systems. Our results present an unequivocal and direct demonstration that pyrabactin is as powerful as ABA in promoting stomatal closure in abaxial epidermis.

Pyrabactin is as powerful as ABA in inducing stomatal closure
-------------------------------------------------------------

Pyrabactin caused a marked reduction in stomatal aperture. The effective concentrations, as well as the effect of pyrabactin on stomatal closure, were quite similar to ABA ([Fig. 1](#fig1){ref-type="fig"}). In contrast, apyrabactin did not induce closure of stomata suggesting that only pyrabactin can mimic ABA during stomatal closure. [@bib22] have reported that pyrabactin caused the inhibition of seed germination like ABA, and facilitated the binding of PP2C with PYR1 during seed germination, while apyrabactin did not. These observations demonstrate that pyrabactin is an agonist of ABA, while apyrabactin is not an agonist. Several effects of ABA, such as the inhibition of seed germination or the promotion of stomatal closure are reversed by FC ([@bib26]; [@bib31]). The stomatal closure caused by pyrabactin was also reversed completely by FC ([Fig. 2](#fig2){ref-type="fig"}), reconfirming our observations that pyrabactin is a strong mimic of ABA, in its effect on stomata.

Signalling components during pyrabactin-induced stomatal closure
----------------------------------------------------------------

The signalling components involved during ABA-induced stomatal closure have been extensively studied. After the initial recognition of ABA signal, through the ABA-PYR/PYL/RCAR-PP2C complex, the ABA-responsive kinases are activated. Subsequently, the guard cell pH becomes alkaline, the membrane-bound NADPH oxidase becomes active, the ROS levels are elevated, followed by a rise in NO levels ([@bib28]; [@bib2]; [@bib6]; [@bib11]). On exposure to pyrabactin too, there were marked increases in pH, ROS, and NO levels ([Fig. 3](#fig3){ref-type="fig"}). Again, apyrabactin, an inactive analogue, did not cause any significant changes in the signalling components of guard cells ([Fig. 3](#fig3){ref-type="fig"}). It was therefore concluded that pyrabactin is an active analogue of ABA, in relation to its influence on stomatal function and signal transduction in guard cells. The present study illustrated that pyrabactin could successfully induce stomatal closure and generate small intracellular components, ROS, and NO during stomatal closure besides increasing the cytoplasmic pH. However, the exact mechanism of the induction of these signalling events is not yet known. It is quite possible that pyrabactin induces ROS and NO production in guard cells by the mediation of PYR/PYL/RCARs, PP2Cs, and OST1/SnRK2.6.

The kinetics of the rise in pH/ROS/NO as indicated by the respective fluorophores ([Fig. 4](#fig4){ref-type="fig"}) suggested that there was marked similarity in the sequence of changes due to pyrabactin or ABA. The ability of DPI and L-NAME to dampen the pyrabactin-induced rise in ROS/NO indicates that NADPH oxidase and putative NOS play an important role during pyrabactin effects. That the action of either pyrabactin or ABA required the alkalinization of guard cells was evident by the ability of butyrate to prevent the rise in pH as well as closure ([Figs 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}). The effect of pyrabactin on stomatal closure and its dependence on rise in pH/ROS/NO of guard cells strikes a strong similarity with the action of ABA as well as methyl jasmonate ([@bib28]; [@bib6], [@bib7]).

ABA and pyrabactin compete during stomatal closure
--------------------------------------------------

Further experiments on stomatal closure in response to varying concentrations of pyrabactin, in the presence of fixed concentration of ABA and vice versa, revealed interesting information on the apparent *IC*~50~ and *K*~D~ values of pyrabactin in relation to ABA ([Fig. 7](#fig7){ref-type="fig"}). The method followed here is similar to that used for examining the ethylene effects on bud and flower drop of *Begonia* in the presence of the gaseous ethylene-binding inhibitor, silver thiosulphate ([@bib25]). The apparent *IC*~50~ for pyrabactin did not change much in the presence of ABA or vice versa ([Fig. 7a, b](#fig7){ref-type="fig"}). By contrast, the *K*~D~ of pyrabactin or ABA (about 4--5 mM) was elevated in the presence of ABA or pyrabactin ([Fig. 7c, d](#fig7){ref-type="fig"}). These results suggested that pyrabactin was competing with ABA during the induction of stomatal closure, either at the active site or very close to the active site on ABA receptors. These values of *IC*~50~ or *K*~D~ values for pyrabactin or ABA (4--5 μM) appear high compared with the *IC*~50~ values reported for ABA (60--125 μM) during interaction with PP2C *in vivo* using a reconstituted system ([@bib14]; [@bib22]). However, it has already been noted that the *IC*~50~ values of ABA to interact *in vivo* with PP2C (60 nM) can vary with that for suppressing root growth (3 μM), as observed by [@bib14]. Similarly, *IC*~50~ values of 2--4 μM were reported for pyrabactin during the inhibition of seed germination and hypocotyl elongation ([@bib22]).

The limitations of our experiments are acknowledged. For example, only the amount of pyrabactin or ABA in the external medium is known. The actual concentrations of pyrabactin or ABA within the cells (at the ABA receptor level) would be much less. Further, the rate of movement of pyrabactin or ABA across the guard cell could also vary. These factors can explain the differences in the observed *K*~D~ for pyrabactin/ABA in our experiments (done *in vivo*) and the values obtained during reconstitution attempts (*in vitro*) by [@bib22] and [@bib8]. In *Arabidopsis* seed germination assays, the pyrabactin concentration (100 μM) required to get an effect similar to ABA (10 μM) was almost 10 times higher ([@bib22]; [@bib16]). However, our major point, that pyrabactin and ABA are competiting with each other, seems to be certain.

Concluding remarks
------------------

The ability of pyrabactin, an analogue of ABA, to induce stomatal closure in *Pisum sativum* leaf abaxial epidermis was as powerful as ABA. This observation opens up an exciting possibility of using pyrabactin as an anti-transpirant. However, it is necessary to explore the possibility of synthesizing pyrabactin and/or analogues at an affordable price for suitable application in agriculture. Since the pattern of signalling components in response to pyrabactin and the reversal of pyrabactin effects by modulators was quite similar to that of ABA, it is suggested that pyrabactin and similar synthetic compounds could be quite useful in studying the signal transduction mechanisms in guard cells as well as in other plant tissues. Being quite similar to ABA in its mode of action, pyrabactin offers a promising potential for use in improving the plant adaptation to drought or other stress conditions.
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